Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects

In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high e...

Full description

Saved in:
Bibliographic Details
Published in:Journal of nanobiotechnology 2022-06, Vol.20 (1), p.276-20, Article 276
Main Authors: Kiaie, Seyed Hossein, Majidi Zolbanin, Naime, Ahmadi, Armin, Bagherifar, Rafieh, Valizadeh, Hadi, Kashanchi, Fatah, Jafari, Reza
Format: Article
Language:English
Subjects:
Analysis
Antigens
Cancer
Cholesterol
Clinical trials
Coronaviruses
COVID-19
Cytotoxicity
Dendritic cell
Dendritic cells
Disease
Efficiency
Gene expression
Genetic engineering
Genomes
Health aspects
Immune response
Immune system
Immunogenicity
Immunology
Immunotherapy
Infectious diseases
Lipid nanoparticles
Lipids
Lymphocytes
Macrophages
Messenger RNA
mRNA
mRNA delivery
Nanoparticles
Pandemics
Pharmacokinetics
Pharmacologic response
Pharmacology
Polyethylene glycol
Proteins
Public health
Review
Synthesis
Toll-like receptors
Vaccines
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials.
ISSN:1477-3155
1477-3155
DOI:10.1186/s12951-022-01478-7